---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-24-000059"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:23:33.469241+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xencor Q3 net loss $45.1M ($0.71 EPS), revenue down 82% YoY; cash $754M

## Summary
- Net loss of $45.1M ($0.71 diluted EPS) vs net loss of $24.3M ($0.40) in Q3 2023.
- Revenue of $10.7M, down 82% YoY from $59.2M, driven by lower milestone and royalty revenue.
- Cash and marketable securities $754.3M as of Sept 30, 2024, up from $697M at Dec 31, 2023; includes $189.2M net proceeds from September public offering.
- Program updates: XmAb942 Phase 1 started; plamotamab Phase 1b/2a in RA planned H1 2025; XmAb808 DLTs in highest dose cohort.
- Amgen's xaluritamig advancing to Phase 3 in mCRPC; Xencor expects 2024 year-end cash $690-710M, funding into 2028.

## SEC filing metadata
- accession: 0001326732-24-000059
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000059/0001326732-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000059/xncr-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-24-000059
- JSON: https://secwatch.observer/filing/0001326732-24-000059.json
- Plain text: https://secwatch.observer/filing/0001326732-24-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.